280 related articles for article (PubMed ID: 21323588)
21. The diagnostic utility of cytokeratin 19 in differentiating malignant from benign thyroid lesions.
Wa Kammal WS; Yahaya A; Shah SA; Abdullah Suhaimi SN; Mahasin M; Mustangin M; Md Isa N
Malays J Pathol; 2019 Dec; 41(3):293-301. PubMed ID: 31901914
[TBL] [Abstract][Full Text] [Related]
22. Proteomic identification of new biomarkers and application in thyroid cytology.
Torres-Cabala C; Bibbo M; Panizo-Santos A; Barazi H; Krutzsch H; Roberts DD; Merino MJ
Acta Cytol; 2006; 50(5):518-28. PubMed ID: 17017437
[TBL] [Abstract][Full Text] [Related]
23. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
24. Expression of Mcl-1 and Ki-67 in Papillary Thyroid Carcinomas.
Maia FF; Vassallo J; Pinto GA; Pavin EJ; Matos PS; Zantut-Wittmann DE
Exp Clin Endocrinol Diabetes; 2016 Apr; 124(4):209-14. PubMed ID: 27123780
[TBL] [Abstract][Full Text] [Related]
25. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
[TBL] [Abstract][Full Text] [Related]
26. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of S100C in thyroid lesions.
Torres-Cabala C; Panizo-Santos A; Krutzsch HC; Barazi H; Namba M; Sakaguchi M; Roberts DD; Merino MJ
Int J Surg Pathol; 2004 Apr; 12(2):107-15. PubMed ID: 15173915
[TBL] [Abstract][Full Text] [Related]
28. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
30. Sorting nexin 5 of a new diagnostic marker of papillary thyroid carcinoma regulates Caspase-2.
Ara S; Kikuchi T; Matsumiya H; Kojima T; Kubo T; Ye RC; Sato A; Kon S; Honma T; Asakura K; Hasegawa T; Himi T; Sato N; Ichimiya S
Cancer Sci; 2012 Jul; 103(7):1356-62. PubMed ID: 22486813
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
32. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
33. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
34. Measurement of the expression of oncofetal fibronectin mRNA in thyroid carcinomas by competitive reverse transcription-polymerase chain reaction.
Higashiyama T; Takano T; Matsuzuka F; Liu G; Miyauchi A; Yokozawa T; Morita S; Kuma K; Shiba E; Noguchi S; Amino N
Thyroid; 1999 Mar; 9(3):235-40. PubMed ID: 10211598
[TBL] [Abstract][Full Text] [Related]
35. Can CD10 be used as a diagnostic marker in thyroid pathology?
Yegen G; Demir MA; Ertan Y; Nalbant OA; Tunçyürek M
Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
[TBL] [Abstract][Full Text] [Related]
36. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization.
Katoh R; Kawaoi A; Miyagi E; Li X; Suzuki K; Nakamura Y; Kakudo K
Mod Pathol; 2000 May; 13(5):570-6. PubMed ID: 10824930
[TBL] [Abstract][Full Text] [Related]
37. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry.
Feilchenfeldt J; Tötsch M; Sheu SY; Robert J; Spiliopoulos A; Frilling A; Schmid KW; Meier CA
Mod Pathol; 2003 Nov; 16(11):1117-23. PubMed ID: 14614051
[TBL] [Abstract][Full Text] [Related]
38. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
39. A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis.
Matsumoto F; Fujii H; Abe M; Kajino K; Kobayashi T; Matsumoto T; Ikeda K; Hino O
Hum Pathol; 2006 Dec; 37(12):1592-600. PubMed ID: 16949643
[TBL] [Abstract][Full Text] [Related]
40. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
